Protea Biosciences 10-Q/A 18 Aug 16 2016 Q2 Quarterly report (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 15, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	true
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1,335,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		133,720,519
Amendment Description	The purpose of this Amendment No. 1 to Protea Biosciences Group, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2016 (the “Form 10-Q”) is to correct typographical errors in the Going Concern section of Note 1 to the Consolidated Financial Statements and in Item 5 of Part II in the Form 10-Q filed with the Securities and Exchange Commission on August 15, 2016 and to provide information regarding current Bylaws adopted by Protea Biosciences Group, Inc. on August 16, 2016.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 174,005	$ 6,450
Accounts receivable, less allowance for doubtful accounts of $3,900 and $3,000 as of June 30, 2016 and December 31, 2015, respectively	375,081	195,823
Inventory	146,946	111,087
Prepaid expenses	122,047	98,231
Total current assets	818,079	411,591
Property and equipment, net	2,846,519	2,626,907
Deposits and other noncurrent assets	5,248	5,248
Total Assets	3,669,846	3,043,746
Current liabilities
Current maturities on short and long-term debt, net of discount	3,437,516	1,323,594
Accounts payable	1,299,203	1,338,367
Bank line of credit	0	3,000,000
Obligations to stockholders, net of discount	2,676,500	2,574,500
Derivative liabilities	1,689,218	962,401
Other current liabilities	507,520	391,308
Total current liabilities	9,609,957	9,590,170
Bank line of credit	3,000,000	0
Long-term debt, net of current maturities	1,918,508	1,726,158
Total Liabilities	14,528,465	11,316,328
Commitments and Contingencies
Stockholders’ Deficit
Preferred stock ($0.0001 par value; 10,000,000 shares authorized; none issued or outstanding as of June 30, 2016 and December 31, 2015)	0	0
Common stock ($0.0001 par value; 250,000,000 shares authorized; 133,720,519 and 133,146,250 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively)	13,372	13,315
Additional paid-in capital	71,618,843	71,311,572
Accumulated deficit	(82,490,749)	(79,597,608)
Accumulated other comprehensive (loss) income	(85)	139
Total Stockholders’ Deficit	(10,858,619)	(8,272,582)
Total Liabilities and Stockholders’ Deficit	$ 3,669,846	$ 3,043,746

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 3,900	$ 3,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	133,720,519	133,146,250
Common stock, shares outstanding	133,720,519	133,146,250

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Gross revenue	$ 581,764	$ 458,076	$ 1,057,102	$ 848,605
Cost of revenue	(489,605)	(171,203)	(693,980)	(315,769)
Gross profit	92,159	286,873	363,122	532,836
Selling, general and administrative expenses	(1,388,139)	(1,782,828)	(2,992,542)	(3,790,569)
Research and development expenses	(139,502)	(306,615)	(372,112)	(689,365)
Loss from operations	(1,435,482)	(1,802,570)	(3,001,532)	(3,947,098)
Other income (expense)
Gains from sales of investment	675,000	0	1,312,100	0
Gains (losses) from disposal of assets	(329)	57,105	(511)	56,231
Gain from insurance recovery	45,952	0	45,952	0
Interest expense	(373,345)	(326,891)	(523,674)	(490,941)
Debt conversion inducement cost	0	0	0	(60,419)
Change in fair value of derivative liabilities	(719,349)	(237,014)	(726,817)	(836,182)
Other income (expense)	(45)	4,462	1,341	6,003
Total other income (expense)	(372,116)	(502,338)	108,391	(1,325,308)
Loss before income taxes	(1,807,598)	(2,304,908)	(2,893,141)	(5,272,406)
Provision for income taxes	0	0	0	0
Net loss	(1,807,598)	(2,304,908)	(2,893,141)	(5,272,406)
Foreign currency translation adjustment	(272)	657	(224)	265
Total comprehensive loss	$ (1,807,870)	$ (2,304,251)	$ (2,893,365)	$ (5,272,141)
Weighted average number of shares of Common stock outstanding - basic and diluted (in shares)	133,687,552	106,157,191	133,494,583	100,243,815
Net loss per share - basic and diluted (per shares)	$ (0.01)	$ (0.02)	$ (0.02)	$ (0.05)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - 6 months ended Jun. 30, 2016 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Balance at Dec. 31, 2015	$ (8,272,582)	$ 0	$ 13,315	$ 71,311,572	$ (79,597,608)	$ 139
Balance (in shares) at Dec. 31, 2015		0	133,146,250
Issuance of common stock upon conversion of accrued interest	41,393	$ 0	$ 16	41,377	0	0
Issuance of common stock upon conversion of accrued interest (in shares)		0	165,573
Issuance of common stock for services	75,000	$ 0	$ 30	74,970	0	0
Issuance of common stock for services (in shares)		0	300,000
Issuance of common stock with short-term convertible note	27,174	$ 0	$ 11	27,163	0	0
Issuance of common stock with short-term convertible note (in shares)		0	108,696
Warrants issued with short-term convertible notes	29,224	$ 0	$ 0	29,224	0	0
Warrants to be issued to Placement Agent	5,436	0	0	5,436	0	0
Anti-dilution warrants to be issued	6,878	0	0	6,878	0	0
Stock-based compensation	122,223	0	0	122,223	0	0
Net loss	(2,893,141)			0	(2,893,141)	0
Foreign currency translation adj.	(224)	0	0	0	0	(224)
Balance at Jun. 30, 2016	$ (10,858,619)	$ 0	$ 13,372	$ 71,618,843	$ (82,490,749)	$ (85)
Balance (in shares) at Jun. 30, 2016		0	133,720,519

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (2,893,141)	$ (5,272,406)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	319,128	356,055
Stock-based compensation	122,223	159,154
Issuance of common stock and warrants for services	75,000	191,683
Issuance of preferred and common stock for accrued interest	0	192,785
Accretion of original issue discount on short-term convertible notes	145,681	107,527
Accretion of warrants and debt issue costs on short-term convertible notes	105,255	117,041
Debt conversion inducement cost	0	60,419
Capitalized interest on debt modification	0	34,596
(Gains) losses from disposal of assets	511	(56,231)
Gains from sales of investment	(1,312,100)	0
Gain from insurance recovery	(45,952)	0
Bad debt expense	0	119,230
Expense from the change in fair value of derivative liabilities	726,817	836,182
Net changes in certain assets and liabilities:
Accounts receivable	(179,258)	(24,024)
Prepaid expenses	(23,816)	(151,723)
Inventory	521	149,379
Other noncurrent assets	0	(93,014)
Accounts payable	(39,164)	35,787
Other current liabilities	157,604	(20,020)
Net cash used in operating activities	(2,840,691)	(3,257,580)
Cash flows from investing activities:
Purchase of and deposits on equipment	(7,817)	(44,132)
Proceeds from sale of equipment	75	134,169
Proceeds from sale of investment	1,312,100	0
Proceeds from insurance recovery	45,952	0
Net cash provided by investing activities	1,350,310	90,037
Cash flows from financing activities:
Proceeds from advances from stockholders	176,375	848,000
Payments on advances from stockholders	(74,376)	0
Proceeds from issuances of debt to stockholders	0	200,000
Proceeds from issuances of debt	2,060,000	2,000,000
Payments of debt issuance costs	(302,707)	(309,345)
Payments on debt	(7,783)	(141,890)
Payments on capital leases	(193,349)	(169,325)
Proceeds from sale of preferred stock, net	0	538,327
Net cash provided by financing activities	1,658,160	2,965,767
Effect of exchange rate changes on cash	(224)	265
Net increase (decrease) in cash	167,555	(201,511)
Cash, beginning of period	6,450	322,877
Cash, end of period	174,005	121,366
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	122,354	124,294
Supplemental disclosure of non-cash investing and financing activities:
Equipment acquired by capital lease	567,888	516,832
Debt converted to preferred stock	0	550,260
Dividends paid in preferred stock	0	156,056
Issuance of common stock upon conversion of accrued interest	41,393	0
Warrants to be issued to Placement Agent	5,436	170,418
Anti-dilution warrants to be issued	6,878	0
Debt issuance costs	$ 5,000	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	Description of Business and Basis of Presentation The Company Protea Biosciences Group, Inc. (referred to herein as “Protea,” “the Company,” “we,” “us” and “our”) is an emerging growth, molecular information company that has developed a revolutionary platform technology that enables the direct analysis, mapping and display of biologically active molecules in living cells and tissue samples. The technology platform offers new, unprecedented capabilities useful to the pharmaceutical, diagnostic, clinical research, agricultural and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, known as “big data,” obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other molecules which are the biologically active molecular products of all living cells and life forms. Our technology is used to improve pharmaceutical development and life science research productivity and outcomes, and to extend and add value to other technologies that are used in research and development, such as three-dimensional tissue models, biomarker discovery, synthetic biologicals and mass spectrometry. In particular, the Company believes that its ability to rapidly provide comprehensive molecular image-based datasets addresses a universal need of the pharmaceutical, diagnostic and clinical research and life science industries. The Company’s commercial development is centered on three lines of business: · Molecular information services – We believe that we are the commercial leader in providing multi-modal Mass Spectrometry Imaging (“MSI”), combining Laser Ablation Electrospray Ionization (“LAESI®”), Matrix Assisted Laser Desorption Ionization (“MALDI”) and optical microscopy. Our proprietary services enable the identification and quantitation of both small molecules (e.g., lipids and metabolites) and large molecules (e.g., proteins) and our services portfolio, inclusive of MSI, proteomics, metabolomics, lipidomics and bioinformatics is unique in the industry. Our clients include major pharmaceutical, chemical and biotechnology companies; · LAESI® instrument platform – we offer our proprietary LAESI® DP-1000 instrument, software and bioanalytical consumables to corporate · Molecular diagnostics and clinical research – we apply our multi-modal MSI technologies and workflows in partnership with top-tier medical research institutions to co-develop new molecular diagnostic tests that the company believes can be used to improve the diagnosis and prognosis of cancer and provide requisite information useful in predicting the outcome of cancer treatment. Our current test development programs target the differential diagnosis and prognosis of malignant melanoma and the molecular profiling of subpopulations of cells in lung adenocarcinoma. Basis of Presentation The unaudited Consolidated Financial Statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. In the opinion of management, these statements have been prepared on a basis consistent with the December 31, 2015 audited Consolidated Financial Statements and include all material adjustments, consisting of normal recurring adjustments and the elimination of material intercompany transactions and balances, necessary for a fair presentation of the Company’s consolidated financial position and results of operations for the interim periods presented. These unaudited, interim, Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include certain information and footnotes normally required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. The consolidated results of operations for the three and six months ended June 30, 2016 are not necessarily indicative of the results of operations for the full fiscal year. These Consolidated Financial Statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on March 16, 2016 (“2015 Form 10-K”). Certain amounts included in the Company’s Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2015 have been reclassified to conform to 2016 classifications. Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to hold a nonbinding advisory vote of shareholders on executive compensation and any golden parachute payments not previously approved. The Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our consolidated financial statements may not be comparable to companies that comply with public company effective dates. We will remain an “emerging growth company” for up to five years following our initial public offering, that is, until February 2019, although we will lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30. To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures, and; (3) the requirement to provide only two years of audited financial statements instead of three years. Critical Accounting Policies Information with respect to the Company’s critical accounting policies which management believes are the most important to the portrayal of the Company’s reported results of operations and financial condition and that require management’s most difficult, subjective or complex judgements, often as the result of the need to make estimates about the effects of matters that are inherently uncertain, is contained in Part II, Item 7 of our 2015 Form 10-K. Recently Issued Accounting Pronouncements There were no changes to the recently issued accounting pronouncements as described in the consolidated financial statements included in our 2015 Form 10-K, except as related to the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Update 2015-03, “Interest–Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). This standard update, which was issued in April 2015, requires an entity to present debt issuance costs on the balance sheet as a direct deduction from the related debt liability as opposed to an asset. Amortization of the costs will continue to be reported as interest expense. The update is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2015. Accordingly, the Company adopted ASU 2015-03 as of January 1, 2016; the adoption of this accounting standard update did not have a material impact on the Company’s consolidated financial statements. As mentioned above, as permitted under the JOBS Act, the Company has elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Going Concern The Company’s Consolidated Financial Statements included in this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings as well as sales of certain assets. Substantially all of the Company’s property and equipment are security for outstanding indebtedness. We will continue to require substantial funds to support our molecular information services business and advance global commercialization of our LAESI® instrument platform and service outstanding debt obligations, including scheduled interest and principal payments and fulfilling payment obligations related to debt that has reached maturity. The Company has experienced negative cash flows from operations since inception. Since inception, our operations have been funded primarily through proceeds received from the issuance of debt and sale of equity securities in private placement offerings and, from time-to-time, sales of certain assets. Management intends to continue to meet the Company’s operating cash flow requirements by raising additional funds from the sale of equity or debt securities, the sale of certain assets, and possibly developing corporate development partnerships to advance our molecular information technology development activities by sharing the costs of development and commercialization. For example, we could also enter into a transaction such as a merger with a business that is complimentary to ours. We have also worked closely with various parties that financed our short- and long-term debt to obtain extensions and modifications that deferred or reduced amounts due under these obligations. Such extensions and modifications have included, in certain cases, the issuance of warrants. In addition, three members of the Company’s Board of Directors and the estate of a former board member guarantee payment of the Company’s outstanding bank line of credit. Such extensions, modifications and guarantees have been an important part of the Company’s ability to manage its liquidity and short-term capital resources. As part of these efforts, the Company has delayed payment to certain vendors and suppliers–as of June 30, 2016, the Company’s accounts payable balance of $ 1,299,203 1,168,426 970,859 198,000 We have sold a majority of our investment in AzurRx BioPharma, Inc. (“AzurRx”) as a means of obtaining additional cash. As discussed in Note 3 Sales of Investment, we raised proceeds of $ 1,312,100 190,000 25 1.7 On May 27, 2016, the Company filed a Form S-1 Registration Statement (“Form S-1”) with the SEC with the goal of raising $ 15,000,000 Since inception, we have been successful in raising funds and selling certain assets to fund our operations and believe that we will be successful in obtaining the necessary capital resources to fund our operations going forward; however, there are no assurances that we will be able to secure any additional funding or capital resources or the terms and conditions of any such arrangements. These factors raise substantial doubt about our ability to continue as a going-concern. The accompanying Consolidated Financial Statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Gross Revenue

Gross Revenue	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	2. Gross Revenue Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Molecular information services $ 494,821 $ 219,064 $ 711,873 $ 389,708 LAESI® instrument platform 7,126 152,625 186,921 305,987 Research products 79,817 86,387 158,308 152,910 Gross revenue $ 581,764 $ 458,076 $ 1,057,102 $ 848,605

Sales of Investment

Sales of Investment	6 Months Ended
	Jun. 30, 2016
Disclosure Text Block Supplement [Abstract]
Cost and Equity Method Investments Disclosure [Text Block]	3. Sales of Investment In the first quarter of 2016, the Company notified AzurRx of its intent to convert 71 0.0001 0.0001 The conversion rate was 24,393.65 shares of AzurRx Common Stock per share of AzurRx Preferred Stock 1,731,949 1,016,941 637,100 550,000 675,000 As of June 30, 2016, the Company’s ownership interest in AzurRx included 265,757 3.6 In July 2016, the Company sold an additional 140,000 190,000 125,757 1.7

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	4. Derivative Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. However, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all of its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB Accounting Standards Codification 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity. See also Note 5 Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Derivatives and Fair Value [Text Block]	5. Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants) The Company has issued certain financial instruments, such as convertible debt and equity financing arrangements, which include variable conversion rates, anti-dilution provisions (“down-round protection”) and detachable warrants that are: (i) not afforded equity classification; (ii) embody risks not clearly and closely related to host contracts, or; (iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities at fair value at the issuance date. Subsequent changes in fair value are recorded through the Consolidated Statement of Operations and Comprehensive Loss. For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “down-round protection,” that are valued using the “Monte Carlo Simulation” technique. This technique, while the majority of inputs are Level 2, necessarily incorporates a capital raise assumption which is unobservable and, therefore, a Level 3 input. As of June 30, 2016, a range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows: Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 1.37 – 4.75 0.26% and 0.58% 77.27% 100% Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to financial instruments that are convertible into shares of the Company’s Common Stock (in particular, convertible notes with variable conversion rates), warrants issued in conjunction with debt and Common Stock issuances or warrants issued to a Placement Agent related to the sale of financial instruments. See also Note 12 Debt and Note 15 Warrants. The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair value measurements as of June 30, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 1,274,980 $ – $ – $ 1,274,980 Derivative liabilities – warrants 225,104 – – 225,104 Derivative liabilities – convertible debt 189,134 – – 189,134 Total $ 1,689,218 $ – $ – $ 1,689,218 Fair value measurements as of December 31, 2015 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 777,002 $ – $ – $ 777,002 Derivative liabilities – warrants 185,399 – – 185,399 Total $ 962,401 $ – $ – $ 962,401 The Company’s assessment of the probability of future capital raises is considered to be high. Such capital raise activities are estimated to take place at levels that are unlikely, but could possibly result in anti-dilution triggers (currently at $ 0.25 189,134 Six Months Ended June 30, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015 497,978 8,101 – 506,079 Fair value of variable conversion rate for convertible debentures issued in 2016 (a) – – 189,134 189,134 Fair value of derivative liabilities associated with other financial instruments issued in 2016 (b) – 31,604 – 31,604 Balance as of June 30, 2016 $ 1,274,980 $ 255,104 $ 189,134 $ 1,689,218 (a) See also Note 12 Debt (b) See also Note 15 Warrants

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	6. Net Loss per Share Basic and diluted loss per common share is computed based on the weighted average number of shares of Common Stock outstanding, or 133,687,552 and 133,494,583 100,243,815 103,624,925 79,823,000

Inventory

Inventory	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	7. Inventory June 30, 2016 December 31, 2015 Work-in-progress $ 137,328 $ 98,437 Finished goods 9,618 12,650 Total inventory $ 146,946 $ 111,087

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	8. Property and Equipment Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Software 3 years June 30, 2016 December 31, 2015 Lab equipment $ 7,128,799 $ 6,617,038 Computer equipment 554,167 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 Accumulated depreciation (5,240,425) (4,934,321) Property and equipment, net $ 2,846,519 $ 2,626,907 For the three and six months ended June 30, 2016, depreciation expense was $ 160,135 319,128 181,084 356,055 During the three months ended June 30, 2016, the Company received proceeds from an insurance claim of $ 45,952

Bank Line of Credit

Bank Line of Credit	6 Months Ended
	Jun. 30, 2016
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	9. Bank Line of Credit The Company has a line of credit with a bank that is authorized to $ 3,000,000 The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum July 12, 2018 3,000,000

Obligations to Stockholders

Obligations to Stockholders	6 Months Ended
	Jun. 30, 2016
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	10. Obligations to Stockholders During the six months ended June 30, 2016, the Company received advances equal to an aggregate of $ 176,375 74,375 32,500 2,547,500 2,676,500 1,117,000 1,559,500 On May 31, 2016, one of the two outstanding interest-bearing promissory notes with a stockholder reached maturity. As of the date of this report, the Company had not made the required payment of $ 200,000 See Note 13 Common Stock related to the conversion of accrued interest on promissory notes issued by the Company to Summit Resources, Inc. (“Summit”), an affiliate of Steve Antoline, a member of the Company’s Board of Directors, and accounts payable by the Company to Summit, into shares of Common Stock.

Other Current Liabilities

Other Current Liabilities	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Other Current Liabilities June 30, 2016 December 31, 2015 Accrued expenses $ 35,209 $ 28,728 Accrued interest 192,157 108,731 Accrued warranty expense 64,293 50,000 Accrued payroll and benefits 147,628 124,183 Unearned revenue 68,233 79,666 Other payables and accrued expenses $ 507,520 $ 391,308

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Debt and Capital Leases Disclosures [Text Block]	12. Debt Short-Term Convertible Notes Issued in May and June 2016 In May and June 2016, the Company issued a series of 20 1,950,000 1,560,000 448,750 1,501,250 390,000 10.0 0.25 85 82,941 1,374,892 342,707 210,305 22,097 In connection with the issuance of the Second Quarter 2016 Convertible Debentures, the Company paid to a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) that acted as the placement agent (“Placement Agent”) an aggregate of approximately $ 187,200 1,365,000 0.25 25,343 As discussed under Note 17 Evaluation of Subsequent Events, the Company issued additional, similar convertible debentures and accompanying warrants in July 2016. Short-Term Convertible Note issued in March 2016 On March 4, 2016, the Company issued to St. George Investments LLC (“St. George Investments”), an Accredited Investor, a 23 655,000 500,000 150,000 5,000 108,696 27,174 1,637,500 0.75 70 The relative fair value of the St. George Investments Warrant was estimated to be $ 12,773 27,174 66,391 75,000 66,928 98,387 655,000 51,613 22,389 4,398 11,232 In connection with the March 2016 Convertible Note, the Company paid to a Placement Agent an aggregate of approximately $ 60,000 491,250 0.25 2,456 , See Note 15 Warrants below related to the triggering of an anti-dilution provision included in the St. George Investments Warrant in May 2016. Convertible Promissory Notes with WVJITB The Company has outstanding two convertible promissory notes with the West Virginia Jobs Investment Trust Board (“WVJITB”). One is an 18 290,000 3 400,000 290,000 300,000 On December 31, 2015, the Company and WVJITB entered into another addendum whereby the maturity dates of both promissory notes were extended to March 31, 2016. In return for the extension, in February 2016, the Company granted WVJITB a five-year warrant to purchase 590,000 0.40 200,000 300,000 10.0 2,478 Promissory Note with WVDO As of June 30, 2016, the Company was five months is arrears on scheduled principal and interest payments on an outstanding note payable to the West Virginia Development Office (“WVDO”). The deferral amount totaled $ 40,173 8,035 Capital Leases In June 2016, the Company entered into a new four-year capital lease for three pieces of equipment that had a value of $ 549,543 From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of June 30, 2016, the Company had seven capital lease obligations outstanding with imputed interest rates ranging from 5.04 9.45 1,831,471 Total debts outstanding, including capital lease obligations, are as follows (table excludes the outstanding balance of the bank line of credit as of December 31, 2015 because the outstanding balance was presented as a current liability at that date as discussed in Note 9 Bank Line of Credit; table excludes advances and other loans from stockholders as discussed in Note 10 Obligations to Stockholders): June 30, 2016 December 31, 2015 Note Payable to the WVDO $ 92,873 $ 100,656 Note Payable to the WVEDA (a) 143,312 143,312 Note Payable to the WVIJDC (b) 139,229 139,229 Note Payable to the WVEDA (a) 572,148 572,148 Note Payable to the WVIJDC (b) 581,987 581,987 Note Payable to the WVJITB 289,628 290,000 Note Payable to the WVJITB 299,628 300,000 Note Payable to the WVEDA (a) 168,362 168,362 Convertible debentures 2,605,000 – Capital leases 1,128,597 754,058 Bank line of credit 3,000,000 – Total 9,020,764 3,049,752 Less: current portion (3,437,516) (1,323,594) Less: unamortized original-issue discount (232,693) – Less: unamortized debt issuance costs (432,047) – Long-term portion $ 4,918,508 $ 1,726,158 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council Future required minimum Year Ended December 31: principal payments 2016 $ 3,788,873 2017 709,169 2018 3,514,743 2019 449,246 2020 and thereafter 558,733 Total $ 9,020,764

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Common Stock [Text Block]	13. Common Stock The Company is authorized to issue a total of 260,000,000 250,000,000 0.0001 10,000,000 0.0001 Conversion of Accrued Interest and Accounts Payable In February 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $ 33,333 8,060 450,000 0.40 945 Advertising Services Agreement In March 2016, the Company entered into an agreement with an advertising firm for certain services to be rendered to the Company over an estimated ninety-day period (the “Media Advertising Agreement”). Besides cash compensation, the Media Advertising Agreement required the Company to issue 150,000 37,500 Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2015 133,146,250 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance (a) 165,573 $ 0.25 – 41,393 16 41,377 Issuance (b) 108,696 $ 0.25 – 27,174 11 27,163 Issuance (c) 300,000 $ 0.25 – 75,000 30 74,970 Balance as of June 30, 2016 133,720,519 $ 58,393,786 $ 2,502,870 $ 13,372 $ 60,883,663 (a) See above under Conversion of Accrued Interest and Accounts Payable (b) Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt) (c) See above under Advertising Services Agreement On December 1, 2015, the Company’s stockholders approved a Certificate of Amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of Common Stock, within a range of no less than one-for-fifteen (1:15) and no more than one-for-twenty-five (1:25), with such final ratio to be determined by the Board of Directors, in its sole discretion (the “Reverse Split”), and with such Reverse Split to be effective at such time and date within one year after stockholder approval. As of the date of this report, the Company’s Board of Directors had not enacted the Reverse Split and, therefore, the information presented in this report does not include the effects of any such transaction.

Stock Options and Stock-Based C

Stock Options and Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	14. Stock Options and Stock-Based Compensation In 2002, the Board adopted the 2002 Equity Incentive Plan (the “2002 Plan”) that governed equity awards to employees, members of the Board of Directors, and consultants of the Company. Under the 2002 Plan, 450,000 4,150,000 12,500,000 The types of awards permitted under the Plans include qualified incentive stock options (“ISO”), non-qualified stock options (“NQO”), and restricted stock. Each stock option shall be exercisable at such times and subject to such terms and conditions as the Board of Directors may specify. Stock options generally vest over four years and expire no later than ten years from the date of grant. Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2015 10,050,086 $ 0.69 7.26 Granted – $ – Exercised – $ – Cancelled or expired (825,000) $ 0.17 Outstanding as of June 30, 2016 9,225,086 $ 0.70 6.84 Exercisable as of December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable as of June 30, 2016 5,398,038 $ 0.92 5.51 Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.25 2,543,336 453,547 $ 0.48 150,000 28,125 $ 0.50 79,000 79,000 $ 0.53 595,000 148,750 $ 0.55 3,632,000 2,462,866 $ 0.80 20,000 20,000 $ 1.25 230,000 230,000 $ 1.50 1,761,000 1,761,000 $ 2.00 214,750 214,750 $ 0.25 – $2.00 9,225,086 6.84 $ 0.70 5,398,038 $ 0.92 As of June 30, 2016, the total aggregate intrinsic value for stock options currently exercisable and stock options outstanding was $ 0 0.15 Stock options Weighted average Non-vested as of December 31, 2015 5,111,422 $ 0.153 Granted – – Forfeited (825,000) $ 0.175 Vested (234,874) $ 0.208 Non-vested as of June 30, 2016 4,051,548 $ 0.151 The fair value of non-vested stock options to be recognized in future periods is $ 529,791 1.95 122,223 159,154 Six Months Ended June 30, 2016 2015 Selling, general, and administrative expense $ 113,741 $ 137,092 Research and development expense 8,482 22,062 Total stock-based compensation $ 122,223 $ 159,154 There were no stock options granted during the six months ended June 30, 2016. The weighted average grant-date fair value of stock options granted during the six months ended June 30, 2015 was $ 0.31 Six Months Ended June 30, 2016 2015 Weighted average risk-free interest rate N/A 1.67 % Volatility factor N/A 66.26 % Weighted average expected life (in years) N/A 8 Dividend rate N/A 0 % The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar public companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SEC Staff Accounting Bulletin No. 110, “Simplified” method).

Warrants

Warrants	6 Months Ended
	Jun. 30, 2016
Warrants [Abstract]
Warrants [Text Block]	15. Warrants In connection with the issuance of the Second Quarter 2016 Convertible Debentures (see Note 12 Debt above), the Company granted each investor a three-year warrant to purchase shares of the Company’s Common Stock at an exercise price of $ 0.325 5,850,001 25,364 The St. George Investments Warrant (see Note 12 Debt above for additional information related to this warrant and the related short-term convertible note) includes an anti-dilution provision that requires the Company to reduce the exercise price for the warrant for any subsequent issuances of Common Stock, or any instrument or securities that are convertible into or exercisable for shares of Common Stock, if the effective price for any such issuance is at an effective price per share that is less than the exercise price for the St. George Investments Warrant. Such a triggering event occurred upon issuance of the first of the Second Quarter 2016 Convertible Debentures, each of which are convertible into shares of the Company’s Common Stock at $0.25 per share. Effective May 20, 2016, the exercise price of the St. George Investment Warrant was reduced to $ 0.25 4,912,500 1,637,500 6,879 4,509 See Note 12 Debt and Note 13 Common Stock for information related to the issuance of warrants to Summit, WVJITB, and a Placement Agent for the purchase of 450,000 1,180,000 1,856,250 As of June 30, 2016, warrants to purchase 82,715,770 11,620 The following table summarizes the activity of the Company’s warrants: Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2015 71,342,894 $ 0.77 2.37 Granted 14,989,751 $ 0.30 3.21 Exercised – $ – Cancelled or expired (3,616,875) $ 2.00 Outstanding as of June 30, 2016 82,715,770 $ 0.62 2.21 The following table summarizes information about warrants as of June 30, 2016: Warrants outstanding Weighted Weighted average average remaining contractual exercise Exercise price Outstanding life (in years) price $ 0.250 12,163,895 $ 0.310 7,500,000 $ 0.325 5,850,001 $ 0.350 14,831,098 $ 0.360 2,845,000 $ 0.400 1,630,000 $ 0.500 2,250,523 $ 0.750 11,065,144 $ 0.800 1,415,000 $ 1.100 19,054,350 $ 1.120 263,750 $ 2.000 722,300 $ 2.200 98,320 $ 2.250 1,296,389 $ 0.20 – $2.25 82,715,770 2.21 $ 0.62

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and Contingencies Legal Proceedings The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In management’s opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations. Warranty Reserve The Company provides for a one-year warranty with the sale of its LAESI® instrument. As the Company does not currently have sufficient historical data on warranty claims, the Company’s estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its products. As of June 30, 2016 and December 31, 2015, the Company has accrued warranty expense of $ 64,293 50,000 University License Agreements The Company has agreements with West Virginia University (“WVU”) and George Washington University (GWU) related to in-licensed technologies as follows: WVU The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation (“WVURC”), a nonprofit West Virginia corporation acting for and on behalf of WVU. Under the terms of this agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery, for therapeutic, diagnostic and all other commercial fields worldwide. Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology. GWU I science advisor 4,781 15,535 9,445 9,445 107,446 104,705 In November 2012, the Company entered into a Patent License Agreement with GWU for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (“LISMA”) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays (Nanophotonic arrays, or “NAPA”). Under the terms of this agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $ 25,000 12,500 20,000 30,000 7 5 50 6 4 1,500 2,500 3,500 6,000 1,500 6,000 5,000 In January 2014, the Company became a subcontractor to GWU in a multi-year project with the Defense Advanced Research Projects Agency (“DARPA”) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within thirty (30) days of exposure. We have commercialized a NAPA-based product out of this arrangement that is currently being sold to research laboratories performing small molecule analysis. COAST Project In 2014, the Company entered into an agreement with Omics2Image B.V. (“O2I”) related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (the “COAST Project”). As part of this arrangement, the Company agreed to commit € 60,000 76,000

Evaluation of Subsequent Events

Evaluation of Subsequent Events	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	17. Evaluation of Subsequent Events Gain on Sale of Investment In July 2016 the Company sold an additional 140,000 190,000 Advances from Stockholders Subsequent to June 30, 2016, the Company repaid advances totaling $ 25,444 2,651,056 Short-Term Convertible Debentures Issued in July 2016 In July 2016 the Company issued a 20 63,750 51,000 12,750 10.0 0.325 191,250 In connection with the issuance of the July 2016 Convertible Debentures, the Company paid to a Placement Agent an aggregate of $ 4,200 44,625 0.25 Issuance of Common Stock for Advertising Services On July 1, 2016 the Company entered into a second advertising services agreement with the same advertising firm (the “Revised Media Advertising Agreement”). The terms for the Revised Media Advertising Agreement are substantially similar to the initial agreement (see Note 13 Common Stock above for additional information), including a ninety service period, but the Company issued 300,000 Adoption of the Second Amended and Restated Bylaws On August 16, 2016, the Company further amended and restated its Bylaws (the “Second Amended and Restated Bylaws”) in their entirety. The Second Amended and Restated Bylaws were approved and adopted by the Board of Directors. The key change of the Second Amended and Restated Bylaws from the previously adopted Amended and Restated Bylaws is the provision, in accordance with Section 228 of the Delaware General Corporation Law, that actions to be taken by stockholders at a meeting can be taken by stockholders without a meeting by a consent or consents in writing, setting forth the actions so taken, signed by the holders of outstanding stock having at least the voting power that would be necessary to authorize or take such action at a meeting. The Second Amended and Restated Bylaws are filed as Exhibit 3.2 to this report and incorporated herein by reference.

Gross Revenue (Tables)

Gross Revenue (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Revenue from External Customers by Products and Services [Table Text Block]	The Company recognizes revenue from three major components: molecular information services, LAESI® instrument platform and research products. Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Molecular information services $ 494,821 $ 219,064 $ 711,873 $ 389,708 LAESI® instrument platform 7,126 152,625 186,921 305,987 Research products 79,817 86,387 158,308 152,910 Gross revenue $ 581,764 $ 458,076 $ 1,057,102 $ 848,605

Fair Value of Financial Asset25

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Inputs, Instruments Classified in Shareholders' Equity, Quantitative Information [Table Text Block]	As of June 30, 2016, a range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows: Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 1.37 – 4.75 0.26% and 0.58% 77.27% 100%
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair value measurements as of June 30, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 1,274,980 $ – $ – $ 1,274,980 Derivative liabilities – warrants 225,104 – – 225,104 Derivative liabilities – convertible debt 189,134 – – 189,134 Total $ 1,689,218 $ – $ – $ 1,689,218 Fair value measurements as of December 31, 2015 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – common stock $ 777,002 $ – $ – $ 777,002 Derivative liabilities – warrants 185,399 – – 185,399 Total $ 962,401 $ – $ – $ 962,401
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis: 189,134 Six Months Ended June 30, 2016 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of January 1, 2016 $ 777,002 $ 185,399 $ – $ 962,401 Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015 497,978 8,101 – 506,079 Fair value of variable conversion rate for convertible debentures issued in 2016 (a) – – 189,134 189,134 Fair value of derivative liabilities associated with other financial instruments issued in 2016 (b) – 31,604 – 31,604 Balance as of June 30, 2016 $ 1,274,980 $ 255,104 $ 189,134 $ 1,689,218 (a) See also Note 12 Debt (b) See also Note 15 Warrants

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at: June 30, 2016 December 31, 2015 Work-in-progress $ 137,328 $ 98,437 Finished goods 9,618 12,650 Total inventory $ 146,946 $ 111,087

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Software 3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following: June 30, 2016 December 31, 2015 Lab equipment $ 7,128,799 $ 6,617,038 Computer equipment 554,167 540,212 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 Accumulated depreciation (5,240,425) (4,934,321) Property and equipment, net $ 2,846,519 $ 2,626,907

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other current liabilities consist of the following at: June 30, 2016 December 31, 2015 Accrued expenses $ 35,209 $ 28,728 Accrued interest 192,157 108,731 Accrued warranty expense 64,293 50,000 Accrued payroll and benefits 147,628 124,183 Unearned revenue 68,233 79,666 Other payables and accrued expenses $ 507,520 $ 391,308

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total debts outstanding, including capital lease obligations, are as follows (table excludes the outstanding balance of the bank line of credit as of December 31, 2015 because the outstanding balance was presented as a current liability at that date as discussed in Note 9 Bank Line of Credit; table excludes advances and other loans from stockholders as discussed in Note 10 Obligations to Stockholders): June 30, 2016 December 31, 2015 Note Payable to the WVDO $ 92,873 $ 100,656 Note Payable to the WVEDA (a) 143,312 143,312 Note Payable to the WVIJDC (b) 139,229 139,229 Note Payable to the WVEDA (a) 572,148 572,148 Note Payable to the WVIJDC (b) 581,987 581,987 Note Payable to the WVJITB 289,628 290,000 Note Payable to the WVJITB 299,628 300,000 Note Payable to the WVEDA (a) 168,362 168,362 Convertible debentures 2,605,000 – Capital leases 1,128,597 754,058 Bank line of credit 3,000,000 – Total 9,020,764 3,049,752 Less: current portion (3,437,516) (1,323,594) Less: unamortized original-issue discount (232,693) – Less: unamortized debt issuance costs (432,047) – Long-term portion $ 4,918,508 $ 1,726,158 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows (table excludes advances and other loans from stockholders as discussed in Note 10 Obligations to Stockholders): Future required minimum Year Ended December 31: principal payments 2016 $ 3,788,873 2017 709,169 2018 3,514,743 2019 449,246 2020 and thereafter 558,733 Total $ 9,020,764

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Common Stock issued and outstanding is as follows: Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2015 133,146,250 Various $ 58,393,786 $ 2,359,303 $ 13,315 $ 60,740,153 Issuance (a) 165,573 $ 0.25 – 41,393 16 41,377 Issuance (b) 108,696 $ 0.25 – 27,174 11 27,163 Issuance (c) 300,000 $ 0.25 – 75,000 30 74,970 Balance as of June 30, 2016 133,720,519 $ 58,393,786 $ 2,502,870 $ 13,372 $ 60,883,663 (a) See above under Conversion of Accrued Interest and Accounts Payable (b) Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt) (c) See above under Advertising Services Agreement

Stock Options and Stock-Based31

Stock Options and Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2015 10,050,086 $ 0.69 7.26 Granted – $ – Exercised – $ – Cancelled or expired (825,000) $ 0.17 Outstanding as of June 30, 2016 9,225,086 $ 0.70 6.84 Exercisable as of December 31, 2015 4,938,664 $ 1.01 5.59 Exercisable as of June 30, 2016 5,398,038 $ 0.92 5.51
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at June 30, 2016: Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.25 2,543,336 453,547 $ 0.48 150,000 28,125 $ 0.50 79,000 79,000 $ 0.53 595,000 148,750 $ 0.55 3,632,000 2,462,866 $ 0.80 20,000 20,000 $ 1.25 230,000 230,000 $ 1.50 1,761,000 1,761,000 $ 2.00 214,750 214,750 $ 0.25 – $2.00 9,225,086 6.84 $ 0.70 5,398,038 $ 0.92
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not yet vested: Stock options Weighted average Non-vested as of December 31, 2015 5,111,422 $ 0.153 Granted – – Forfeited (825,000) $ 0.175 Vested (234,874) $ 0.208 Non-vested as of June 30, 2016 4,051,548 $ 0.151
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows: Six Months Ended June 30, 2016 2015 Selling, general, and administrative expense $ 113,741 $ 137,092 Research and development expense 8,482 22,062 Total stock-based compensation $ 122,223 $ 159,154
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the stock option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: Six Months Ended June 30, 2016 2015 Weighted average risk-free interest rate N/A 1.67 % Volatility factor N/A 66.26 % Weighted average expected life (in years) N/A 8 Dividend rate N/A 0 %

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]	The following table summarizes the activity of the Company’s warrants: Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2015 71,342,894 $ 0.77 2.37 Granted 14,989,751 $ 0.30 3.21 Exercised – $ – Cancelled or expired (3,616,875) $ 2.00 Outstanding as of June 30, 2016 82,715,770 $ 0.62 2.21
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	The following table summarizes information about warrants as of June 30, 2016: Warrants outstanding Weighted Weighted average average remaining contractual exercise Exercise price Outstanding life (in years) price $ 0.250 12,163,895 $ 0.310 7,500,000 $ 0.325 5,850,001 $ 0.350 14,831,098 $ 0.360 2,845,000 $ 0.400 1,630,000 $ 0.500 2,250,523 $ 0.750 11,065,144 $ 0.800 1,415,000 $ 1.100 19,054,350 $ 1.120 263,750 $ 2.000 722,300 $ 2.200 98,320 $ 2.250 1,296,389 $ 0.20 – $2.25 82,715,770 2.21 $ 0.62

Description of Business and B33

Description of Business and Basis of Presentation (Details Textual) - USD ($)	1 Months Ended		6 Months Ended
	Jul. 31, 2016	May 27, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Nature of Business [Line Items]
Substantial Doubt about Going Concern, Conditions or Events			We will remain an “emerging growth company” for up to five years following our initial public offering, that is, until February 2019, although we will lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30.
Bank Overdrafts			$ 198,000
Proceeds from Sale of Equity Method Investments			1,312,100	$ 0
Estimated Value of Stock to Be Issued		15,000,000
Increase (Decrease) in Accounts Payable			(39,164)	$ 35,787
OverDue Terms [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable			1,168,426
Past Due 90 Days [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable			970,859
AzurRx BioPharma Inc [Member]
Nature of Business [Line Items]
Proceeds from Sale of Equity Method Investments			$ 1,312,100
Equity Method Investment, Ownership Percentage					25.00%
AzurRx BioPharma Inc [Member] | Subsequent Event [Member]
Nature of Business [Line Items]
Proceeds from Sale of Equity Method Investments	$ 190,000
Equity Method Investment, Ownership Percentage	1.70%

Gross Revenue (Details)

Gross Revenue (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Gross revenue	$ 581,764	$ 458,076	$ 1,057,102	$ 848,605
Molecular Information Services [Member]
Segment Reporting Information [Line Items]
Gross revenue	494,821	219,064	711,873	389,708
LAESI Instrument Platform [Member]
Segment Reporting Information [Line Items]
Gross revenue	7,126	152,625	186,921	305,987
Research Products [Member]
Segment Reporting Information [Line Items]
Gross revenue	$ 79,817	$ 86,387	$ 158,308	$ 152,910

Sales of Investment (Details Te

Sales of Investment (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Mar. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Subsidiary or Equity Method Investee [Line Items]
Sale of Stock, Number of Shares Issued in Transaction				265,757
Preferred Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Conversion Basis			The conversion rate was 24,393.65 shares of AzurRx Common Stock per share of AzurRx Preferred Stock
Common Stock, Shares Outstanding		133,720,519		133,720,519	133,146,250
AzurRx BioPharma Inc [Member]
Subsidiary or Equity Method Investee [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		3.60%		3.60%
AzurRx BioPharma Inc [Member] | Subsequent Event [Member]
Subsidiary or Equity Method Investee [Line Items]
Equity Method Investment, Ownership Percentage	1.70%
Common Stock, Shares Outstanding	125,757
Convertible Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Preferred Stock, Par or Stated Value Per Share			$ 0.0001
Common Stock, Par or Stated Value Per Share			$ 0.0001
Series A Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			71
Common Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of Stock, Number of Shares Issued in Transaction		550,000	1,016,941
Sale of Stock, Consideration Received on Transaction		$ 675,000	$ 637,100
Common Stock [Member] | AzurRx BioPharma Inc [Member] | Subsequent Event [Member]
Subsidiary or Equity Method Investee [Line Items]
Sale of Stock, Number of Shares Issued in Transaction	140,000
Sale of Stock, Consideration Received on Transaction	$ 190,000
Common Stock [Member] | Convertible Preferred Stock [Member]
Subsidiary or Equity Method Investee [Line Items]
Conversion of Stock, Shares Issued			1,731,949

Fair Value of Financial Asset36

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details) - Derivative Financial Instruments, Liabilities [Member]	6 Months Ended
	Jun. 30, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Volatility	77.27%
Probability of a capital raise	100.00%
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected life (years)	1 year 4 months 13 days
Risk-free rate	0.26%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Expected life (years)	4 years 9 months
Risk-free rate	0.58%

Fair Value of Financial Asset37

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 1) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 1,689,218	$ 962,401
Derivative liabilities - convertible debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	189,134	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liabilities - convertible debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liabilities - convertible debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	1,689,218	962,401
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - convertible debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	189,134
Derivative liabilities - common stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	1,274,980	777,002
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	1,274,980	777,002
Derivative liabilities - warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	225,104	185,399
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 225,104	$ 185,399

Fair Value of Financial Asset38

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 2)	6 Months Ended
	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	$ 962,401
Balance as of June 30, 2016	1,689,218
Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	0
Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015	0
Fair value of variable conversion rate for convertible debentures issued in 2016	189,134	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0
Balance as of June 30, 2016	189,134
Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	185,399
Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015	8,101
Fair value of variable conversion rate for convertible debentures issued in 2016	0	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	31,604	[2]
Balance as of June 30, 2016	225,104
Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	777,002
Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015	497,978
Fair value of variable conversion rate for convertible debentures issued in 2016	0	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	0	[2]
Balance as of June 30, 2016	1,274,980
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	962,401
Unrealized loss (income) on derivative liabilities outstanding as of December 31, 2015	506,079
Fair value of variable conversion rate for convertible debentures issued in 2016	189,134	[1]
Fair value of derivative liabilities associated with other financial instruments issued in 2016	31,604	[2]
Balance as of June 30, 2016	1,689,218
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of June 30, 2016	189,134
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	185,399
Balance as of June 30, 2016	225,104
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of January 1, 2016	777,002
Balance as of June 30, 2016	$ 1,274,980
[1]	See also Note 12 Debt
[2]	See also Note 15 Warrants

Fair Value of Financial Asset39

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details Textual)	Jun. 30, 2016$ / shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Share Price	$ 0.25

Net Loss per Share (Details Tex

Net Loss per Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Weighted Average Number of Shares Outstanding, Basic and Diluted	133,687,552	106,157,191	133,494,583	100,243,815
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			103,624,925	79,823,000

Inventory (Details)

Inventory (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Work-in-progress	$ 137,328	$ 98,437
Finished goods	9,618	12,650
Total Inventory	$ 146,946	$ 111,087

Property and Equipment (Details

Property and Equipment (Details)	6 Months Ended
	Jun. 30, 2016
Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicle [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Life of lease

Property and Equipment (Detai43

Property and Equipment (Details 1) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Lab equipment	$ 7,128,799	$ 6,617,038
Computer equipment	554,167	540,212
Office equipment	191,248	191,248
Leasehold improvements	212,730	212,730
Accumulated depreciation	(5,240,425)	(4,934,321)
Property and equipment, net	$ 2,846,519	$ 2,626,907

Property and Equipment (Detai44

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 160,135	$ 181,084	$ 319,128	$ 356,055
Proceeds from Insurance Settlement, Investing Activities	$ 45,952		$ 45,952	$ 0

Bank Line of Credit (Details Te

Bank Line of Credit (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)	$ 3,000,000	$ 3,000,000
Line of Credit Facility, Interest Rate Description		The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum
Line of Credit Facility, Amount Outstanding (in dollars)	$ 3,000,000	$ 3,000,000	$ 3,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date	Jul. 12, 2018

Obligations to Stockholders (De

Obligations to Stockholders (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	May 31, 2016	Dec. 31, 2015
Loans Payable to Stockholders [Line Items]
Due to Officers or Stockholders, Current	$ 2,676,500		$ 2,574,500
Notes Payable		$ 200,000
Interest Bearing Promissory Notes [Member]
Loans Payable to Stockholders [Line Items]
Due to Officers or Stockholders, Current	1,117,000
Non-Interest Bearing Promissory Notes [Member]
Loans Payable to Stockholders [Line Items]
Due to Officers or Stockholders, Current	1,559,500
Directors and Stock holders [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Related Party Debt	176,375
Three Directors [Member]
Loans Payable to Stockholders [Line Items]
Repayments of Related Party Debt	74,375
Stockholders [Member]
Loans Payable to Stockholders [Line Items]
Repayments of Related Party Debt	$ 32,500

Other Current Liabilities (Deta

Other Current Liabilities (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Payables And Accruals [Line Items]
Accrued expenses	$ 35,209	$ 28,728
Accrued interest	192,157	108,731
Accrued warranty expense	64,293	50,000
Accrued payroll and benefits	147,628	124,183
Unearned revenue	68,233	79,666
Other payables and accrued expenses	$ 507,520	$ 391,308

Debt (Details)

Debt (Details) - USD ($)		Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		$ 9,020,764	$ 3,049,752
Less: current portion		(3,437,516)	(1,323,594)
Less: unamortized original-issue discount		(232,693)	0
Less: unamortized debt issuance costs		(432,047)	0
Long-term portion		1,918,508	1,726,158
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		92,873	100,656
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	143,312	143,312
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	139,229	139,229
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	572,148	572,148
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	581,987	581,987
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		289,628	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		299,628	300,000
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	168,362	168,362
Capital leases [Member]
Debt Instrument [Line Items]
Capital Lease Obligations		1,128,597	754,058
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		2,605,000	0
Less: unamortized debt issuance costs		(51,613)
Line of Credit [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		$ 3,000,000	$ 0
[1]	West Virginia Economic Development Authority
[2]	West Virginia Infrastructure and Jobs Development Council

Debt (Details 1)

Debt (Details 1) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Future Required Minimum Principal Repayments
2,016	$ 3,788,873
2,017	709,169
2,018	3,514,743
2,019	449,246
2020 and thereafter	558,733
Total	$ 9,020,764	$ 3,049,752

Debt (Details Textual)

Debt (Details Textual) - USD ($)	Mar. 04, 2016	Jun. 30, 2016	May 31, 2016	Feb. 29, 2016	Apr. 30, 2012	Mar. 31, 2012	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Jul. 31, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 22,097					$ 22,097	$ 22,097
Accretion Expense								0
Debt Instrument, Unamortized Discount		432,047					432,047	432,047		$ 0
Payments of Debt Issuance Costs								302,707	$ 309,345
Notes Payable			$ 200,000
Stock Issued During Period, Value, Conversion of Convertible Securities								27,174
West Virginia Jobs Investment Trust Board [Member]
Debt Instrument [Line Items]
Proceeds from Issuance of Warrants										10,000,000
April 2012 Promissory Notes [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities								300,000
Common Stock [Member]
Debt Instrument [Line Items]
Equity, Fair Value Disclosure		27,174					27,174	27,174
Stock Issued During Period, Value, Conversion of Convertible Securities								11
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment							75,000	98,387
Debt Instrument, Face Amount	$ 655,000
Debt Conversion, Converted Instrument, Shares Issued	108,696
Unsecured Debt Original Issue Discount Percentage	23.00%
Proceeds from Issuance of Unsecured Debt	$ 500,000
Warrants Not Settleable in Cash, Fair Value Disclosure		4,398					4,398	4,398				$ 12,773
Accretion Expense							66,391	$ 66,928
Warrants Expiration Term								5 years
Legal Fees	5,000
Debt Instrument, Unamortized Discount		51,613					51,613	$ 51,613
Debt Conversion, Converted Instrument, Amount	$ 27,174
Debt Conversion, Converted Instrument, Warrants or Options Issued	1,637,500
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Percentage of Closing Bid Price	70.00%
Convertible Debt		$ 655,000					$ 655,000	$ 655,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1,856,250					1,856,250	1,856,250
Debt Issuance Costs, Net		$ 22,389					$ 22,389	$ 22,389
Stock Issued								$ 11,232
Convertible Note and Warrant [Member]
Debt Instrument [Line Items]
Warrants Expiration Term								3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25					$ 0.25	$ 0.25
Payments of Debt Issuance Costs								$ 2,456
Placement Agent Commissions Paid								$ 60,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		491,250					491,250	491,250
Convertible Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	$ 150,000
Second Quarter 2016 Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		10.00%					10.00%	10.00%
Debt Instrument, Face Amount		$ 1,950,000					$ 1,950,000	$ 1,950,000
Unsecured Debt Original Issue Discount Percentage							20.00%
Proceeds from Issuance of Unsecured Debt							$ 1,560,000
Interest Expense, Debt							82,941
Debt Instrument, Unamortized Discount		342,707					342,707	342,707
Payments of Debt Issuance Costs							187,200
Convertible Debt		1,374,892					$ 1,374,892	1,374,892
Debt Instrument, Term							6 months
Debt Instrument ,Original Issue Discount							$ 390,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger							85.00%
Debt Issuance Costs, Net		$ 210,305					$ 210,305	$ 210,305
Second Quarter 2016 Convertible Notes [Member] | Placement Agent [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,365,000					1,365,000	1,365,000
Warrants Not Settleable in Cash, Fair Value Disclosure		$ 25,343					$ 25,343	$ 25,343
Warrants Expiration Term							3 years
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25					$ 0.25	$ 0.25
Second Quarter 2016 Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Nov 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date							Nov. 30, 2016
Debt Instrument, Face Amount		$ 448,750					$ 448,750	$ 448,750
Second Quarter 2016 Convertible Notes [Member] | Second Quarter 2016 Convertible Notes Due Dec 2016 [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date							Dec. 31, 2016
Debt Instrument, Face Amount		$ 1,501,250					$ 1,501,250	$ 1,501,250
Maximum [Member] | Second Quarter 2016 Convertible Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 0.25					$ 0.25	$ 0.25
Notes Payable to West Virginia Development Office [Member]
Debt Instrument [Line Items]
Notes Payable		$ 40,173					$ 40,173	$ 40,173
Notes Payable to West Virginia Development Office [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Notes Payable											$ 8,035
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument						18 months
Long-term Debt, Gross (in dollars)						$ 290,000
Debt Instrument, Face Amount						$ 290,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1,180,000					1,180,000	1,180,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument					3 months
Long-term Debt, Gross (in dollars)					$ 400,000
Debt Instrument, Face Amount					$ 300,000
Capital Leases [Member]
Debt Instrument [Line Items]
Leases Secured Equipment cost		$ 549,543						$ 1,831,471
Capital Leases, Lease Term		4 years
Capital Leases [Member] | Maximum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate		9.45%					9.45%	9.45%
Capital Leases [Member] | Minimum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate		5.04%					5.04%	5.04%
Convertible Promissory Notes with WVJITB [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 200,000
Debt Conversion, Converted Instrument, Warrants or Options Issued										590,000
Payments of Debt Issuance Costs			$ 2,478	$ 2,478
Common Stock Exercise Price										$ 0.40

Common Stock (Details)

Common Stock (Details)	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Class of Stock [Line Items]
Beginning Balance	$ 13,315
Issuance of stock for services	75,000
Ending Balance	$ 13,372
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares) | shares	133,146,250
Issuance of stock, Shares issued (in shares) | shares	300,000
Balance (in shares) | shares	133,720,519
Price Per Share, Beginning Balance (in dollars per share)	Various
Gross Proceeds, Beginning Balance (in dollars)	$ 58,393,786
Gross Proceeds, Ending Balance (in dollars)	58,393,786
Estimated fair value at issuance, Beginning Balance (in dollars)	2,359,303
Estimated fair value at issuance, Ending Balance (in dollars)	2,502,870
Beginning Balance	13,315
Issuance of stock for services	30
Ending Balance	13,372
Additional Paid in Capital, Beginning Balance (in dollars)	60,740,153
Additional Paid in Capital, Ending Balance (in dollars)	$ 60,883,663
Issuance of stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares) | shares	165,573	[1]
Stock Options exercised, Price Per Share (in dollars per share) | $ / shares	$ 0.25	[1]
Issuance of stock, Gross Proceeds (in dollars)	$ 0	[1]
Issuance of stock, Estimated fair value at issuance (in dollars)	41,393	[1]
Issuance of stock for services	16	[1]
Issuance of stock, Additional Paid in Capital (in dollars)	$ 41,377	[1]
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares) | shares	108,696	[2]
Stock Options exercised, Price Per Share (in dollars per share) | $ / shares	$ 0.25	[2]
Issuance of stock, Gross Proceeds (in dollars)	$ 0	[2]
Issuance of stock, Estimated fair value at issuance (in dollars)	27,174	[2]
Issuance of stock for services	11	[2]
Issuance of stock, Additional Paid in Capital (in dollars)	$ 27,163	[2]
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares) | shares	300,000	[3]
Stock Options exercised, Price Per Share (in dollars per share) | $ / shares	$ 0.25	[3]
Issuance of stock, Gross Proceeds (in dollars)	$ 0	[3]
Issuance of stock, Estimated fair value at issuance (in dollars)	75,000	[3]
Issuance of stock for services	30	[3]
Issuance of stock, Additional Paid in Capital (in dollars)	$ 74,970	[3]
[1]	See above under Conversion of Accrued Interest and Accounts Payable
[2]	Shares issued in conjunction with the March 2016 Convertible Note (see Note 12 Debt)
[3]	See above under Advertising Services Agreement

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
	Feb. 29, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Shares Authorized Total		260,000,000
Common Stock, Shares Authorized		250,000,000			250,000,000
Preferred Stock, Shares Authorized		10,000,000			10,000,000
Preferred Stock, Shares Issued		0			0
Preferred Stock, Shares Outstanding		0			0
Paid-In-Kind Interest		$ 0	$ 192,785
Common Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001	$ 0.0001
Preferred Stock, Par or Stated Value Per Share		$ 0.0001		$ 0.0001	$ 0.0001
Payments of Debt Issuance Costs		$ 302,707	$ 309,345
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Description	In February 2016, the Company’s Board of Directors authorized the conversion of an aggregate of $33,333 of accrued interest on promissory notes issued by the Company to Summit and $8,060 of account payable (or a total of $41,393) by the Company to Summit, into 165,573 shares of Common Stock at the rate of $0.25 per share.
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	450,000	450,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.40
Payments of Debt Issuance Costs	$ 945
Term Of Warrants	5 years
Media Advertising Agreement [Member]
Class of Stock [Line Items]
Management Fee Expense		$ 37,500
Common Stock [Member]
Class of Stock [Line Items]
Paid-In-Kind Interest	$ 33,333
Accounts Payable	$ 8,060
Stock Issued During Period, Shares, Issued For Services		300,000
Common Stock [Member] | Media Advertising Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services		150,000

Stock Options and Stock-based53

Stock Options and Stock-based Compensation (Details) - Employee Stock Option [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	10,050,086
Shares, Granted	0
Shares, Exercised	0
Shares, Cancelled or expired	(825,000)
Shares, Outstanding	9,225,086	10,050,086
Shares Exercisable	5,398,038	4,938,664
Weighted Average Exercise Price, Outstanding	$ 0.69
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	0.17
Weighted Average Exercise Price, Outstanding	0.7	$ 0.69
Weighted Average Exercise Price, Exercisable	$ 0.92	$ 1.01
Weighted ave. remaining contractual life (years), Outstanding	6 years 10 months 2 days	7 years 3 months 4 days
Weighted ave. remaining contractual life (years), Exercisable	5 years 6 months 4 days	5 years 7 months 2 days

Stock Options and Stock-based54

Stock Options and Stock-based Compensation (Details 1)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Exercise Price 0.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.25
Options Outstanding (in shares)	2,543,336
Options Exercisable (in shares)	453,547
Exercise Price 0.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.48
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	28,125
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.50
Options Outstanding (in shares)	79,000
Options Exercisable (in shares)	79,000
Exercise Price 0.53 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.53
Options Outstanding (in shares)	595,000
Options Exercisable (in shares)	148,750
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.55
Options Outstanding (in shares)	3,632,000
Options Exercisable (in shares)	2,462,866
Exercise Price 0.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.80
Options Outstanding (in shares)	20,000
Options Exercisable (in shares)	20,000
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.25
Options Outstanding (in shares)	230,000
Options Exercisable (in shares)	230,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.50
Options Outstanding (in shares)	1,761,000
Options Exercisable (in shares)	1,761,000
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750
Exercise Price 0.25 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Limit (in dollars per share) | $ / shares	$ 0.25
Options Outstanding, Exercise Price, Upper Limit (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	9,225,086
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	6 years 10 months 2 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.70
Options Exercisable (in shares)	5,398,038
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.92

Stock Options and Stock-based55

Stock Options and Stock-based Compensation (Details 2) - $ / shares	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Non-vested, Beginning Balance	5,111,422
Shares, Granted	0
Shares, Forfeited	(825,000)
Shares, Vested	(234,874)
Shares, Non-vested at Ending Balance	4,051,548
Weighted Average grant-date fair value, Non-vested, Beginning Balance	$ 0.153
Weighted average grant-date fair Value, Granted	0	$ 0.31
Weighted average grant-date fair value, Forfeited	0.175
Weighted average grant-date fair value, Vested	0.208
Weighted average grant-date fair value, Non-vested, Ending Balance	$ 0.151

Stock Options and Stock-based56

Stock Options and Stock-based Compensation (Details 3) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 122,223	$ 159,154
Selling, general and administrative expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	113,741	137,092
Research and development expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 8,482	$ 22,062

Stock Options and Stock-based57

Stock Options and Stock-based Compensation (Details 4)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate		1.67%
Volatility factor		66.26%
Weighted average expected life (in years)		8 years
Dividend rate		0.00%

Stock Options and Stock-based58

Stock Options and Stock-based Compensation (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$ 122,223	$ 159,154
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0	$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	1 year 11 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested And Expected To Vest Fair Value	$ 529,791
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			4,150,000	450,000
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	12,500,000

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2015	71,342,894
Shares, Granted	14,989,751
Shares, Exercised	0
Shares, Cancelled or expired	(3,616,875)
Shares, Outstanding at June 30, 2016	82,715,770	71,342,894
Weighted Average Exercise Price, Outstanding at December, 2015	$ 0.77
Weighted Average Exercise Price, Granted	0.3
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	2
Weighted Average Exercise Price,Shares, Outstanding at June 30, 2016	$ 0.62	$ 0.77
Weighted Average Remaining Contractual Life (in years), Outstanding	2 years 2 months 16 days	2 years 4 months 13 days
Weighted Average Remaining Contractual Life (in years), Granted	3 years 2 months 16 days

Warrants (Details 1)

Warrants (Details 1) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Exercise Price 0.20 - 2.25 | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.25
Exercise Price 0.20 - 2.25 | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.20
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	82,715,770
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 2 months 16 days	2 years 4 months 13 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.62	$ 0.77
Warrant [Member] | Exercise Price 0.250
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.250
Warrants Outstanding (in shares)	12,163,895
Warrant [Member] | Exercise Price 0.310
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.310
Warrants Outstanding (in shares)	7,500,000
Warrant [Member] | Exercise Price 0.325
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.325
Warrants Outstanding (in shares)	5,850,001
Warrant [Member] | Exercise Price 0.350
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.350
Warrants Outstanding (in shares)	14,831,098
Warrant [Member] | Exercise Price 0.360
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.360
Warrants Outstanding (in shares)	2,845,000
Warrant [Member] | Exercise Price 0.400
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.400
Warrants Outstanding (in shares)	1,630,000
Warrant [Member] | Exercise Price 0.500
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.500
Warrants Outstanding (in shares)	2,250,523
Warrant [Member] | Exercise Price 0.750
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.750
Warrants Outstanding (in shares)	11,065,144
Warrant [Member] | Exercise Price 0.800
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.800
Warrants Outstanding (in shares)	1,415,000
Warrant [Member] | Exercise Price 1.100
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.100
Warrants Outstanding (in shares)	19,054,350
Warrant [Member] | Exercise Price 1.120
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.120
Warrants Outstanding (in shares)	263,750
Warrant [Member] | Exercise Price 2.000
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2
Warrants Outstanding (in shares)	722,300
Warrant [Member] | Exercise Price 2.200
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.200
Warrants Outstanding (in shares)	98,320
Warrant [Member] | Exercise Price 2.250
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.250
Warrants Outstanding (in shares)	1,296,389

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	May 20, 2016	Mar. 04, 2016	Feb. 29, 2016
Class of Warrant or Right [Line Items]
Interest Expense, Other		$ 11,620
Accretion Expense		$ 0
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	82,715,770	82,715,770
Convertible Notes Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.40
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	450,000	450,000			450,000
Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.75
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1,856,250	1,856,250
Accretion Expense	$ 66,391	$ 66,928
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.325	$ 0.325
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,850,001	5,850,001
Investor [Member] | Warrant [Member]
Class of Warrant or Right [Line Items]
Derivative, Fair Value, Net	$ 25,364	$ 25,364
St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.25
Fair Value Adjustment of Warrants		6,879
Accretion Expense		$ 4,509
Convertible Promissory Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1,180,000	1,180,000
Minimum [Member] | St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,637,500
Maximum [Member] | St. George Investments [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			4,912,500
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	82,715,770	82,715,770

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014EUR (€)
Loss Contingencies [Line Items]
Accrued warranties	$ 64,293		$ 64,293		$ 50,000
George Washington University [Member]
Loss Contingencies [Line Items]
Royalty Expenses	4,781	$ 9,445	15,535	$ 9,445
License Costs			25,000
Minimum License Diligence Resources Year Two			12,500
Minimum License Diligence Resources After Year Two			20,000
License and Maintenance Revenue			$ 30,000
Royalties Percentage on Net Sales of Licensed Products			7.00%
Royalties Percentage on Combination Products for Combined Cumulative Net Sales			5.00%
Reduce Royalties Percentage After Net Sales of Licensed Products			6.00%
Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales			4.00%
Minimum Royalties Year One	1,500		$ 1,500
Minimum Royalties Year Two	2,500		2,500
Minimum Royalties Year Three	3,500		3,500
Minimum Royalties Year After Three Year	6,000		6,000
Accrued Royalties, Current	104,705		104,705
Accounts Payable, Current	107,446		107,446
Maximum Cumulative Net Sales Under Patent License Agreement			50,000,000
COAST Project [Member]
Loss Contingencies [Line Items]
Commitments Outstanding						$ 76,000	€ 60,000
REDIchip [Member]
Loss Contingencies [Line Items]
Royalty Expenses	1,500		1,500
Accrued Royalties, Current	5,000		5,000
Accounts Payable, Current	$ 6,000		$ 6,000

Evaluation of Subsequent Even63

Evaluation of Subsequent Events (Details Textual) - USD ($)	Mar. 04, 2016	Jul. 31, 2016	Jun. 30, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Debt Instrument, Unamortized Discount			$ 432,047	$ 0
Unsecured Convertible Debentures [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Debt Instrument, Face Amount	$ 655,000
Unsecured Debt Original Issue Discount Percentage	23.00%
Proceeds from Issuance of Unsecured Debt	$ 500,000
Debt Instrument, Unamortized Discount			$ 51,613
Subsequent Event [Member]
Subsequent Event [Line Items]
Due to Affiliate		$ 2,651,056
Subsequent Event [Member] | July 2016 Convertible Note [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.325
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		191,250
Subsequent Event [Member] | Unsecured Convertible Debentures [Member] | July 2016 Convertible Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Maturity Date		Jan. 31, 2017
Debt Instrument, Face Amount		$ 63,750
Unsecured Debt Original Issue Discount Percentage		20.00%
Proceeds from Issuance of Unsecured Debt		$ 51,000
Debt Instrument, Interest Rate, Effective Percentage		10.00%
Debt Instrument ,Original Issue Discount		$ 12,750
Subsequent Event [Member] | Advances From Stockholders [Member]
Subsequent Event [Line Items]
Due to Affiliate		$ 25,444
Subsequent Event [Member] | Placement Agent [Member] | July 2016 Convertible Note [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		44,625
Debt Instrument, Unamortized Discount		$ 4,200
Warrant Expiration Period		3 years
AzurRx BioPharma Inc [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		140,000
Proceeds from Issuance of Common Stock		$ 190,000
Advertising Firm [Member] | Subsequent Event [Member] | Consideration In Shares [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services		300,000